Pharmaceuticals
The pharmaceutical industry is a EUR 1 trillion sector and has been a major engine of economic growth and scientific advancement for decades. The industry encompasses a wide range of enterprises including large ethical drug multi-nationals (so-called Big Pharma), mid-sized specialty pharmaceutical companies, generic manufacturers, virtual pharmas, small biotechnology and biopharmaceutical firms, and all the various ancillary support and service companies that provide contract research, regulatory guidance, contract sales, and manufacturing technologies and raw materials.
Although growth has not been as robust in recent years—mainly due to price pressures, uncertainty in regulatory/reform measures, and weak drug pipelines— the demographic and structural drivers of demand in healthcare still exist: namely, the continued aging of the global population and the increasing sophistication and wealth of developing nations. Shifting epidemiology patterns and outbreaks, along with new challenges in chronic disease, cancer, heart disease, and degenerative disease will continue to impel the need for ever-better medicines. New understanding and technologies in drug delivery, and most especially in the fields of genomics, proteomics, and molecular biology generally, also hold promise for better therapeutics and a revival of profits.
Although growth has not been as robust in recent years—mainly due to price pressures, uncertainty in regulatory/reform measures, and weak drug pipelines— the demographic and structural drivers of demand in healthcare still exist: namely, the continued aging of the global population and the increasing sophistication and wealth of developing nations. Shifting epidemiology patterns and outbreaks, along with new challenges in chronic disease, cancer, heart disease, and degenerative disease will continue to impel the need for ever-better medicines. New understanding and technologies in drug delivery, and most especially in the fields of genomics, proteomics, and molecular biology generally, also hold promise for better therapeutics and a revival of profits.
Page 2/16
Generics in the Netherlands
August 2013 · MarketLine
Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). € 259,00
OTC Pharmaceuticals in Germany
August 2013 · MarketLine
OTC Pharmaceuticals in Germany industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00
OTC Pharmaceuticals in the Netherlands
August 2013 · MarketLine
OTC Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00
OTC Pharmaceuticals in Mexico
August 2013 · MarketLine
OTC Pharmaceuticals in Mexico industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00
OTC Pharmaceuticals in Hungary
August 2013 · MarketLine
OTC Pharmaceuticals in Hungary industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00
Biotechnology in Belgium
August 2013 · MarketLine
Biotechnology in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). € 259,00
Biotechnology in Europe
August 2013 · MarketLine
Biotechnology in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). € 259,00
OTC Pharmaceuticals in the Czech Republic
August 2013 · MarketLine
OTC Pharmaceuticals in the Czech Republic industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00
Biotechnology in Italy
August 2013 · MarketLine
Biotechnology in Italy industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). € 259,00
OTC Pharmaceuticals in Sweden
August 2013 · MarketLine
OTC Pharmaceuticals in Sweden industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00
Apotex, Inc. - SWOT, Strategy and Corporate Finance Report
July 2013 · MarketLine
Apotex, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00
AAIPharma Services Corporation - SWOT, Strategy and Corporate Finance Report
July 2013 · MarketLine
AAIPharma Services Corporation - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00
Sanofi - SWOT, Strategy and Corporate Finance Report
July 2013 · MarketLine
Sanofi - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00
Chugai Pharmaceutical Co., Ltd. - SWOT, Strategy and Corporate Finance Report
July 2013 · MarketLine
Chugai Pharmaceutical Co., Ltd. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00
Abbott Laboratories - SWOT, Strategy and Corporate Finance Report
July 2013 · MarketLine
Abbott Laboratories - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00
F. Hoffmann-La Roche Ltd - SWOT, Strategy and Corporate Finance Report
July 2013 · MarketLine
F. Hoffmann-La Roche Ltd - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00
IR Biosciences Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Derma Sciences, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Health Management Associates, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
BioMarin Pharmaceutical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Apricus Biosciences, Inc. (formerly NexMed, Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Siemens Healthcare - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Accentia Biopharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
InterMune, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Express Scripts, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Stryker Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Endo Health Solutions, Inc. (formerly Endo Pharmaceuticals Holdings, Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Affitech A/S (formerly Pharmexa A/S) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Santarus, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Ranbaxy Laboratories Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Cornerstone Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Fresenius Kabi AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
TAKARA HOLDINGS, INC. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
BTG plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
GenVec, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Perrigo Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Evotec AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Medivir AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Barr Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Sanofi - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Immunomedics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Hanger, Inc. (formerly Hanger Orthopedic Group, Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Ipsogen SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
MacroGenics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Charles River Laboratories International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Novavax, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Cellectis S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
CytRx Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
July 2013 · MarketLine
Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Options